To further evaluate the effects of PMP22 differential expression on the prognosis of breast cancer, the authors concluded that patients with higher PMP22 expression had a higher risk of dying from cancer than those with the same clinical covariates but with lower PMP22 expression. Here, PMP22 is linked to breast carcinoma.